Olari

Kamux Corporation's Interim Report for January 1--September 30, 2022: Kamux's revenue grew in a challenging market environment, adjusted operating profit decreased significantly

Retrieved on: 
Friday, November 18, 2022
Family, Growth, Audit committee, AGM, Tax, ROE, Financial statement, Friends, Annual, News, Niittykumpu, Annual general meeting, ID, Sale, Econ, Communication, EET, Annual report, Olari, Employment, Chair, Policy, Sanomatalo, Remuneration, EUR, Shareholder, Film, Car dealership, Management, Clothing

"Despite the continued challenging market situation, we succeeded in growing our market share in all our operating countries also during the third quarter.

Key Points: 
  • "Despite the continued challenging market situation, we succeeded in growing our market share in all our operating countries also during the third quarter.
  • Revenue developed positively in all countries as a result of higher average prices, and sales of integrated services continued to develop well.
  • The decrease in operating profit was due to the decline in the number of cars sold and the weakening of margin per car.
  • However, the number of hybrid and electric cars sold by the company increased by 29% compared to the third quarter of 2021.

Olaris Appoints Dr. Dirk Kuypers to Its Scientific Advisory Board

Retrieved on: 
Thursday, September 30, 2021
Bill of rights, British Transplantation Society, Kidney, International Board, Lists of television programs, Precision medicine, Patient, Kidney transplantation, Laboratory, Physician, Health, Metabolomics, Biomarker, Bors, University, Growth, Pharmacology, Risk, Society, Therapeutic drug monitoring, UZ Leuven, TTS, Infection, Department, Olari, Machine learning, Medical device, Dentistry

WALTHAM, Mass., Sept. 30, 2021 /PRNewswire-PRWeb/ -- Olaris, Inc , a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, has appointed Dr. Dirk Kuypers to the Olaris Scientific Advisory Board.

Key Points: 
  • WALTHAM, Mass., Sept. 30, 2021 /PRNewswire-PRWeb/ -- Olaris, Inc , a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, has appointed Dr. Dirk Kuypers to the Olaris Scientific Advisory Board.
  • Dr. Kuypers is Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, Belgium.
  • "Dr. Kuypers is a renowned researcher in the field of kidney transplantation, with a passion for personalizing treatment in renal transplant to ensure recipients do not suffer from complications.
  • I'm looking forward to working with Liz and the team to further the Olaris mission of fundamentally changing how diseases are diagnosed and treated," said Dr. Kuypers.

Kojamo has Agreed on the Construction of Over 900 Apartments in the Helsinki Region

Retrieved on: 
Friday, August 30, 2019
Districts of Espoo, Niittykumpu, Helsinki, Olari, Cities in Europe, Geography of Finland

HELSINKI, Aug. 30, 2019 /PRNewswire/ -- Kojamo has signed co-operation agreements on construction of 905 rental apartments in the Helsinki region.

Key Points: 
  • HELSINKI, Aug. 30, 2019 /PRNewswire/ -- Kojamo has signed co-operation agreements on construction of 905 rental apartments in the Helsinki region.
  • Kojamo announced earlier today an agreement with SRV on construction of 527 Lumo apartments.
  • In addition, Kojamo and Hausia have signed today an co-operation agreement on construction of rental apartments worth approximately EUR 90 million in Espoo in Niittykumpu, Olari and Kirkkojrvi districts.
  • In the process, construction companies were requested to propose investment initiatives for approximately EUR 100 million in the Helsinki region.